Recent research in Annals of Blood (March 2026) highlights a shift in artificial blood development from experimental studies to clinically relevant oxygen therapeutics. The review notes that artificial blood aims to address key limitations of donor blood, including supply shortages, storage issues, and compatibility issues. These products offer immediate availability without cross-matching, reduced infectious risk,…
Login in to view this article:
You need to be logged in to view the rest of this article. Don't have an account? Register for one below.
Subscribe
0 Comments
Oldest
Sponsored Links
